John A. Lewicki - 01 Feb 2026 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Scientific Officer
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
01 Feb 2026
Net transactions value
$0
Form type
4
Filing time
02 Feb 2026, 16:30:10 UTC
Previous filing
28 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lewicki John A. Chief Scientific Officer C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, UNITED KINGDOM /s/ Christine Fox, by power of attorney 02 Feb 2026 0001553352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +139,913 $0.000000 139,913 01 Feb 2026 American Depositary Shares 139,913 $0.4400 Direct F1, F2
transaction MREO Share Options (Right to buy) Award $0 +46,637 $0.000000 46,637 01 Feb 2026 American Depository Shares 46,637 $1.00 Direct F1, F2
transaction MREO Share Options (Right to buy) Award $0 +145,000 $0.000000 145,000 01 Feb 2026 American Depository Shares 145,000 $0.4400 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3 Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.